Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Veru Inc. (VERU) Investors of Class Action and to Actively Participate
Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Veru Inc. (VERU) Investors of Class Action and to Actively Participate
New York, New York--(Newsfile Corp. - February 3, 2023) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Veru Inc. ("Veru" or the "Company") (NASDAQ: VERU) and certain of its officers, on behalf of all persons and entities that purchased, or otherwise acquired Veru common stock during the period from May 11, 2022 to November 9, 2022, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: .
紐約，紐約--（新聞文件公司 -2023 年 2 月 3 日）-布朗斯坦，蓋維茨 & 格羅斯曼有限責任公司通知投資者，已針對 Vuru Inc. 提起集體訴訟（以下簡稱「Vuru」或「公司」）（納斯達克代碼：VERU）及其某些高級職員，代表在 2022 年 5 月 11 日至 2022 年 11 月 9 日（包括「集體期間」）期間購買或以其他方式獲得 Veru 普通股的所有人和實體。鼓勵此類投資者通過訪問該公司的網站加入此案：.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws.
這項集體訴訟旨在彌補被告人因涉嫌違反聯邦證券法所蒙受的損失。
The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements, as well as failed to disclose material adverse facts about the data from the sabizabulin Phase 3 trial and the Company's interactions with the FDA. Specifically, Veru misled its shareholders to believe that the data from the Phase 3 trial was sufficient to support Emergency Use Authorization ("EUA") and even the submission of a New Drug Application ("NDA") without any further studies. VERU's filings therefore concealed the true risks faced by the Company in gaining approval for its EUA request.
投訴指，在整個集體期間，被告人作出虛假和/或具誤導性的陳述，並沒有披露來自 sabizabulin 3 期試驗的數據以及公司與 FDA 的互動的重大不良事實。具體來說，Vuru 誤導其股東認為，第三階段試驗中的數據足以支持緊急使用授權（「EUA」），甚至無需進一步研究即可提交新藥申請（「NDA」）。因此，VERU 提交的文件掩蓋了公司在獲得其 EUA 請求批准時面臨的真實風險。
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm's site: or you may contact Peretz Bronstein, Esq. or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Veru you have until February 6, 2023 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
集體訴訟已經提起。如果您想查看投訴的副本，您可以訪問該公司的網站：或者您可以通過 212-697-6484 與佩雷茲·布朗斯坦聯繫佩雷茲·布朗斯坦的律師和客戶關係經理，雅爾·納森，有限責任公司。如果您在 Veru 遭受損失，則在 2023 年 2 月 6 日之前要求法院指定您為主要原告人。您在任何恢復中分享的能力並不需要您擔任主要原告。
Bronstein, Gewirtz & Grossman, LLC represents investors in securities fraud class actions and shareholder derivative suits. The firm has recovered hundreds of millions of dollars for investors nationwide. Attorney advertising. Prior results do not guarantee similar outcomes.
布朗斯坦，蓋維茨和格羅斯曼有限責任公司代表投資者處理證券欺詐集體訴訟和股東衍生工具訴訟。該公司已為全國投資者收回了數億美元。律師廣告。先前的結果不能保證類似的結果。
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Nathanson
212-697-6484 | info@bgandg.com
聯繫方式：
布朗斯坦, 蓋維茨 & 格羅斯曼, LLC
佩雷茲·布朗斯坦或耶爾·納坦森
212-697-6484 | info@bgandg.com
To view the source version of this press release, please visit
如欲查看此新聞稿的來源版本，請瀏覽